How can erythropoietin be increased in patients with chronic kidney disease?

How to Increase Erythropoietin in CKD Patients

The primary strategy to increase erythropoietin (EPO) in CKD patients is to administer exogenous erythropoiesis-stimulating agents (ESAs) such as recombinant human EPO, as endogenous EPO production progressively fails with declining kidney function and cannot be meaningfully restored. 1

Understanding the Problem

In CKD, the kidney's ability to produce EPO diminishes because renal EPO-producing cells (peritubular interstitial fibroblasts) undergo transdifferentiation into myofibroblasts during the fibrotic process. This transformation is essentially irreversible—these cells lose their EPO-producing capacity as they become part of the fibrotic tissue 2, 3. While the liver attempts to compensate by increasing EPO synthesis (evidenced by altered glycosylation patterns), this compensation is inadequate to prevent anemia 4.

Treatment Algorithm

Step 1: Optimize Iron Status FIRST

Before initiating or increasing EPO therapy, iron deficiency is the most common cause of inadequate EPO response 1:

• Target iron parameters:

  • Transferrin saturation (TSAT) ≥20%
  • Serum ferritin ≥100 ng/mL 1

• For hemodialysis patients:

  • Oral iron is inadequate—use intravenous (IV) iron 1
  • Initial course: 25-100 mg IV iron weekly for 10 weeks 1
  • Maintenance: 250-1,000 mg IV iron per 12 weeks 1
  • Monitor TSAT and ferritin every 3 months 1

• Common pitfall: Starting or escalating ESAs without adequate iron stores leads to functional iron deficiency and treatment failure 1

Step 2: Initiate ESA Therapy

ESAs remain the first-line pharmacologic treatment 5, 6:

• Target hemoglobin: 11-12 g/dL (avoid exceeding 12 g/dL due to cardiovascular risks) 1

• Route selection:

  • Subcutaneous (SC) administration requires 15-50% less EPO than IV and is preferred when feasible 1
  • For hemodialysis patients already at target Hgb switching from IV to SC: reduce dose by 33% 1

• Dosing strategy:

  • Goal is gradual Hgb increase over 2-4 months 1
  • 96% of patients respond to ≤450 units/kg/week IV (or 300 units/kg/week SC) within 4-6 months if iron-replete 1

Step 3: Address EPO Resistance

If target hemoglobin is not achieved despite adequate iron (TSAT ≥20%, ferritin ≥100 ng/mL) and appropriate ESA dosing, evaluate for 1:

1. Infection/inflammation (most common)—check C-reactive protein; EPO resistance resolves when infection clears
2. Chronic blood loss—suspect if increasing ESA doses needed or iron stores fail to replenish despite IV iron
3. Osteitis fibrosa—check intact PTH levels
4. Aluminum toxicity—relevant in certain dialysis populations
5. Hemoglobinopathies—particularly alpha/beta thalassemia (more common in Asian populations)
6. Folate or B12 deficiency—water-soluble vitamins lost in dialysate
7. Multiple myeloma, malnutrition, hemolysis—less common

Emerging Therapies

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) represent a newer approach that stimulates endogenous EPO production by stabilizing HIF 5, 7, 8. However:

• Current guideline position: ESAs remain preferred first-line therapy due to concerns about HIF-PHI cardiovascular safety and limited long-term data 5, 6
• HIF-PHIs may be particularly useful in inflammatory states where ESA resistance occurs 5
• Oral administration offers convenience but monitoring adherence is difficult 5
• Regional regulatory differences exist (more restricted approval in Europe vs. US) 6

Critical Safety Considerations

Do not target hemoglobin >12 g/dL—randomized trials demonstrate increased risks of stroke, hypertension, vascular access thrombosis, and mortality with higher targets 1, 9. The historical practice of normalizing hemoglobin has been definitively shown to cause more harm than benefit.

Monitor for complications:

• Hypertension (common with ESA therapy)
• Thrombotic events (especially with rapid Hgb rise)
• Pure red cell aplasia (rare, antibody-mediated)
• Potential tumor progression in patients with active malignancy 9

Special Populations

• Peritoneal dialysis patients: Can use intraperitoneal EPO administration into a "dry" abdomen if SC/IV not feasible, though doses may need to be higher 1
• Pediatric patients: Weight-adjusted dosing required; children <5 years may need higher doses 1
• Patients with prior stroke or active malignancy: Risks of ESA therapy may outweigh benefits of transfusion avoidance 9

The bottom line: You cannot meaningfully "increase" endogenous EPO production in CKD patients—the damaged kidney cannot be restored to produce adequate EPO. Treatment requires exogenous ESA administration with meticulous attention to iron repletion and avoidance of excessive hemoglobin targets.